A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions
Tourette Syndrome
Interventions
DRUG

TEV-50717

6-, 9-, 12-, 15-, and 18 mg oral tablets

DRUG

Placebo

Placebo matched to TEV-50717 tablets will be taken BID.

Trial Locations (56)

1021

Teva Investigational Site 060-0901, Budapest

1900

Teva Investigational Site 060-1403, La Plata

2170

Teva Investigational Site 060-1802, Liverpool

3052

Teva Investigational Site 060-1801, Parkville

3722

Teva Investigational Site 060-1904, Seoul

4080

Teva Investigational Site 060-2007, Kiev

4209

Teva Investigational Site 060-2005, Kyiv

5500

Teva Investigational Site 060-1404, Mendoza

6351

Teva Investigational Site 060-1902, Seoul

6725

Teva Investigational Site 060-0902, Szeged

10036

Teva Investigational Site 060-0154, New York

21005

Teva Investigational Site 060-2006, Vinnytsia

30329

Teva Investigational Site 060-0168, Atlanta

31503

Teva Investigational Site 060-1105, Krakow

32608

Teva Investigational Site 060-0160, Gainesville

32801

Teva Investigational Site 060-0151, Orlando

32819

Teva Investigational Site 060-0153, Orlando

37000

Teva Investigational Site 060-1603, León

38157

Teva Investigational Site 060-0157, Memphis

40202

Teva Investigational Site 060-0158, Louisville

46256

Teva Investigational Site 060-0152, Indianapolis

48105

Teva Investigational Site 060-0165, Ann Arbor

49101

Teva Investigational Site 060-2003, Dnipropetrovsk

60612

Teva Investigational Site 060-0155, Chicago

60634

Teva Investigational Site 060-0164, Chicago

61068

Teva Investigational Site 060-2001, Kharkiv

61153

Teva Investigational Site 060-2002, Kharkiv

63044

Teva Investigational Site 060-0170, Bridgeton

64460

Teva Investigational Site 060-1602, Monterrey

64610

Teva Investigational Site 060-1604, Monterrey

76104

Teva Investigational Site 060-0163, Fort Worth

80020

Teva Investigational Site 060-1601, Culiacán

80131

Teva Investigational Site 060-1003, Naples

95123

Teva Investigational Site 060-1001, Catania

660003

Teva Investigational Site 060-1504, Pereira

5500515

Teva Investigational Site 060-1501, Medellín

32561-4458

Teva Investigational Site 060-0166, Gulf Breeze

33136-2107

Teva Investigational Site 060-0161, Miami

20852-4219

Teva Investigational Site 060-0167, Rockville

29414-5834

Teva Investigational Site 060-0169, Charleston

37232-2551

Teva Investigational Site 060-0156, Nashville

98201-4077

Teva Investigational Site 060-0162, Everett

C1023AAB

Teva Investigational Site 060-1407, Buenos Aires

C1058AAJ

Teva Investigational Site 060-1401, Buenos Aires

C1425AHQ

Teva Investigational Site 060-1402, Buenos Aires

051050

Teva Investigational Site 060-1503, Bello

78 B 50

Teva Investigational Site 060-1506, Medellín

09121

Teva Investigational Site 060-1005, Cagliari

00165

Teva Investigational Site 060-1004, Rome

80-542

Teva Investigational Site 060-1104, Gdansk

40-123

Teva Investigational Site 060-1101, Katowice

60-693

Teva Investigational Site 060-1102, Poznan

87-100

Teva Investigational Site 060-1106, Torun

02-793

Teva Investigational Site 060-1103, Warsaw

110-744

Teva Investigational Site 060-1901, Seoul

138-736

Teva Investigational Site 060-1903, Seoul

Sponsors
All Listed Sponsors
collaborator

Nuvelution TS Pharma, Inc.

INDUSTRY

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY